Publication: BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
Issued Date
2009-12-15
Resource Type
ISSN
10970215
00207136
00207136
Other identifier(s)
2-s2.0-72449126757
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Cancer. Vol.125, No.12 (2009), 2820-2828
Suggested Citation
Moltira Promkan, Guangming Liu, Pimpicha Patmasiriwat, Subhas Chakrabarty BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. International Journal of Cancer. Vol.125, No.12 (2009), 2820-2828. doi:10.1002/ijc.24684 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27096
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
Other Contributor(s)
Abstract
BRCA1 is a multifunctional tumor-suppressive protein. Many functional aspects of BRCA1 are not fully understood. We used a shRNA approach to probe the function of BRCA1 in human breast cancer cells. Knocking down BRCA1 expression by shRNA in the wild-type BRCA1 human breast cancer MCF-7 and MDA-MB-231 cells resulted in an increase in cell proliferation, anchorage-independent growth, cell migration, invasion and a loss of p21/Waf1 and p27Kip1expression. In BRCA1 knocked-down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel. We also found that cells harboring endogenous mutant or defective BRCA1 (MDA-MB-436 and HCC1937) were highly proliferative and expressed a relatively low level of p21/Waf1 and p27Kip1by comparison to wild-type BRCA1 cells. Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild-type cells. Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. We conclude that BRCA1 down-modulates the malignant behavior of breast cancer cells, promotes the expression of p21/Waf1, p27Kip1and inhibits the expression of survivin. Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel. © 2009 UICC.